Inebilizumab for NMDA receptor encephalitis after initial steroids
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 2 study tests inebilizumab in people with NMDA receptor encephalitis, an immune-related brain condition. It looks to see if adding this treatment after starting steroids (and possibly other first treatments) improves recovery and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have NMDA receptor encephalitis confirmed by a specific antibody test in spinal fluid (CSF).
- You must be at least 12 years old (and if under 18, weigh at least 40 kg).
- You must have had recent treatment: high-dose IV steroids for at least 3 days within the last 90 days, plus either IVIG or plasma exchange in the prior 90 days.
- You should have moderate disability from the illness (Modified Rankin Score 3 or higher).
- You must be willing to come to study visits and follow study procedures through the end of the study.
- If you could become pregnant or have a partner who could, you must follow strict birth control rules during the study and for months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an experimental treatment using tiny particles from stem cells (called exosomes) given through the nose can help people with autoimmune encephalitis. It is for adults who were recently diagnosed and have specific antibodies.
This Phase 2 study tests whether bortezomib can improve outcomes and safety in adults with severe autoimmune encephalitis. It focuses on people whose condition is confirmed by brain-related autoantibodies and who have already received rituximab.
This study tests a new medicine (ART5803) in people whose immune system attacks a brain receptor called NMDAR, causing encephalitis (brain swelling) or psychiatric symptoms. It aims to see if the medicine can reduce symptoms like confusion, memory problems, or psychosis.
This research study looks for new markers in the blood of people with autoimmune encephalitis (a condition where the immune system attacks the brain). It aims to better understand what causes the disease and find new ways to diagnose it.
This study is for people with autoimmune encephalitis, a condition where the immune system attacks the brain. It aims to collect information about this disease to learn more about it and how to treat it.
This study tests a natural bile-derived medicine (Calcus Bovis Sativus) to see if it can help adults with new or recent brain inflammation (encephalitis). It focuses on people whose encephalitis is caused by the immune system or a virus, and who have not fully recovered.
Hear when a new Autoimmune Encephalitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.